Drug Trial Radar · NCT06887127
A Long-term Extension Clinical Study of TLL-018 in Patients With Rheumatoid Arthritis
Last checked: Nov 19, 2026Latest source record: Sep 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
350
Planned (sponsor's estimate)
Start
Mar 10, 2025
Primary completion
Dec 31, 2026
Study completion Dec 31, 2027
Sponsor
- Lead sponsor
- Hangzhou Highlightll Pharmaceutical Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Mar 20, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of the study is to evaluate the long-term safety, tolerability, and efficacy of TLL-018 in patients with rheumatoid arthritis (RA) who have completed a preceding randomized controlled trial with TLL-018.
Conditions
- Rheumatoid Arthritis
Interventions
TLL-018Drug
TLL-018 20 mg BID for 78 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of occurrences and Percentage of Participants with AEs and SAEsTime frame: At Weeks 6, 12, 24, 36, 48, 60, 72, 78
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Peking Union Hospital, Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.